Ranbaxy CEO Arun Sawhney On What’s Next After Lipitor – An Exclusive PharmAsia News Interview (Part 2 of 2)
This article was originally published in PharmAsia News
Ranbaxy Laboratories Ltd. CEO and Managing Director Arun Sawhney stayed away from media interactions for the last four years.
You may also be interested in...
TOKYO - Daiichi Sankyo has initiated operations for its Ranbaxy-supported generics subsidiary in Japan - Daiichi Sanyko Espha - a positive step for the company's established products plans as it awaits news on U.S. FDA action on Ranbaxy
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.